Lisata Therapeutics LSTA 深 滬
等待開盤 11-04 09:30:00 美东时间
1.09
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.09
- 總市值 1177.64万
- 52周最高 5.07
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.9604
- 委 比 0.00%
- 總股本 1080.41万
- 歷史最高 1483.50
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.9604
- 每 手 1
- 風險率 1.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lisata Therapeutics Expands Board, Appoints Independent Director
Lisata Therapeutics ( ($LSTA) ) has shared an update. On October 13, 2026, Lisa...
10-15 04:47
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Lisata Therapeutics announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Farrow, a veteran biopharma CFO with over 15 years of experience, will also serve on the Audit Committee. His expertise in financial leadership and successful commercial launches will support Lisata's Phase 2b programs for severe hypertriglyceridemia and acromegaly. Farrow currently serves as CFO and Chief Strategy Officer of Tar...
10-14 20:05
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Marea Therapeutics has initiated a Phase 2 clinical trial for MAR002, a potential treatment for acromegaly, after positive Phase 1 results showed effective IGF-1 suppression and dosing as infrequently as every two weeks. Acromegaly, caused by excess growth hormone, leads to severe physical and systemic complications. MAR002, a first-in-class monoclonal antibody targeting the growth hormone receptor, aims to provide meaningful control for patients...
10-05 12:00
Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines For Cardioendocrine Diseases
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advanci...
09-17 21:28
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 (as amended, the "Merger Agreement"), seeking, among other things, damages for the benefit of its stockholders and the $2,000,000 termi...
08-04 19:14
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Lisata Therapeutics has filed a lawsuit against Kuva Labs Inc. and its subsidiary over the termination of their merger agreement, seeking damages and a $2 million termination fee. The company is evaluating strategic alternatives to enhance stockholder value, including potential acquisitions, mergers, or asset sales. To reduce expenses, Lisata has implemented a 72% reduction in its workforce, which may impact operations and reputation.
08-04 11:00
Lisata Therapeutics plunges after sale to Kuva Labs terminated
Lisata Therapeutics (LSTA) sank 16% after its planned sale to Kuva Labs was terminated The termination comes after Kuva Labs was unable to obtain sufficient financing to fund its takeover offer, accor...
07-25 00:59
Lisata Therapeutics Ends Kuva Merger, Starts Strategic Review
Lisata Therapeutics ( ($LSTA) ) has shared an announcement. On July 24, 2026, L...
07-25 00:43
Lisata Therapeutics Stock Falls After Hours: Here's Why
Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares slipped in after-hours trading Tuesday after the clinical-stage biotechnology company disclosed an update related to its pending acquisition. Lisata stock closed Tuesday’s regular session down 36.45% at $2.24 before falling 3.57% to $2.16 in after-hours...
07-22 13:03
